Lawson Health Research Institute, P.O. Box 5375
London, ON N6A 4G5
Ms. Mary Gardner
Coordinator, Business Development
T: (519) 685-8500, x 77738
F: (519) 432-7367
E: [email protected]
PLANTIGEN’s goals are to advance the company’s breakthrough research in oral immune regulation by linking expertise in plant biotechnology with specialized knowledge in molecular immunology, clinical medicine and trials design.
PLANTIGEN Inc. is a novel therapeutics discovery company focused on the identification and development of biopharmaceuticals in genetically enhanced plants to prevent and treat disease. PLANTIGEN Inc. has devised a means of producing human proteins to treat life-threatening diseases affecting a significant proportion of the population throughout the industrialized world. Common agricultural crops are used to grow and harvest extremely high-value complex proteins capable of regulating immune responses in humans.
The technology platform (PLANTimmune) for therapeutic protein manufacture is based on a system to synthesize edible target proteins within the leaf tissue of genetically enhanced plants. PLANTIGEN has focused on human proteins capable of triggering a beneficial immune response (ORAmmune) through oral ingestion. These are compounds of therapeutic significance for the treatment of autoimmune diseases such as Type I Diabetes, Crohn’s Disease, Multiple Sclerosis and Organ Transplant Rejection.
PLANTIGEN Inc. is seeking seed capital in the form of equity investment to support future research, clinical studies and business activities in preparation for a later round of public and/or private financing. Revenue during the first three years of operation is to be generated from research grants and milestone payments arising from research collaborations. The cash infusion will leverage PLANTIGEN’s ability to pursue more sources of co-sponsored funding from public sector research and innovation initiatives, while seeking alliances with corporate partners. The financing will support activities to bring PLANTIGEN’s pre-eminent products closer to commercialization and attract investment from larger capitalized Pharmaceutical and Biotechnology Companies.